TR201910701T4 - Kanser terapisine yönelik ro5503781 ve kapesitabin kombinasyonu. - Google Patents
Kanser terapisine yönelik ro5503781 ve kapesitabin kombinasyonu. Download PDFInfo
- Publication number
- TR201910701T4 TR201910701T4 TR2019/10701T TR201910701T TR201910701T4 TR 201910701 T4 TR201910701 T4 TR 201910701T4 TR 2019/10701 T TR2019/10701 T TR 2019/10701T TR 201910701 T TR201910701 T TR 201910701T TR 201910701 T4 TR201910701 T4 TR 201910701T4
- Authority
- TR
- Turkey
- Prior art keywords
- capecitabine
- combination
- cancer therapy
- question
- product
- Prior art date
Links
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title abstract 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004117 capecitabine Drugs 0.000 title abstract 2
- 238000011275 oncology therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
Burada, kanserin eş zamanlı veya art arda gerçekleştirilen tedavisine yönelik a) aşağıda yer alan formül bileşiğini içeren bir birinci bileşeni ve b) kapesitabin içeren bir ikinci bileşeni içeren farmasötik ürünler, söz konusu ürünü içeren kitler ve aynı zamanda söz konusu ürünün uygulanmasıyla kanser hastalarının tedavi edilmesine yönelik yöntemler sağlanmıştır.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361836894P | 2013-06-19 | 2013-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201910701T4 true TR201910701T4 (tr) | 2019-08-21 |
Family
ID=50981495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/10701T TR201910701T4 (tr) | 2013-06-19 | 2014-06-16 | Kanser terapisine yönelik ro5503781 ve kapesitabin kombinasyonu. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20160129033A1 (tr) |
EP (1) | EP3010513B1 (tr) |
JP (1) | JP6239745B2 (tr) |
KR (1) | KR20160007662A (tr) |
CN (1) | CN105307660A (tr) |
BR (1) | BR112015029658A2 (tr) |
CA (1) | CA2912816A1 (tr) |
ES (1) | ES2741003T3 (tr) |
HK (1) | HK1214502A1 (tr) |
MX (1) | MX2015016893A (tr) |
PL (1) | PL3010513T3 (tr) |
RU (1) | RU2015152577A (tr) |
TR (1) | TR201910701T4 (tr) |
WO (1) | WO2014202492A1 (tr) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050227932A1 (en) * | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
WO2007107543A1 (en) * | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
RU2436784C2 (ru) * | 2006-03-22 | 2011-12-20 | Янссен Фармацевтика Н.В. | Ингибиторы взаимодействия между mdm2 и р53 |
WO2008034039A2 (en) * | 2006-09-15 | 2008-03-20 | Nexuspharma Inc. | Novel tetrahydro-isoquinolines |
JP5053674B2 (ja) * | 2007-03-26 | 2012-10-17 | テルモ株式会社 | 耳式体温計 |
SI2326329T1 (sl) * | 2008-08-04 | 2017-06-30 | Wyeth Llc | Antineoplastične kombinacije 4-anilino-3-cianakinolinov in kapecitabina |
US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
-
2014
- 2014-06-16 PL PL14732136T patent/PL3010513T3/pl unknown
- 2014-06-16 JP JP2016520395A patent/JP6239745B2/ja not_active Expired - Fee Related
- 2014-06-16 US US14/896,716 patent/US20160129033A1/en not_active Abandoned
- 2014-06-16 CA CA2912816A patent/CA2912816A1/en not_active Abandoned
- 2014-06-16 MX MX2015016893A patent/MX2015016893A/es unknown
- 2014-06-16 RU RU2015152577A patent/RU2015152577A/ru not_active Application Discontinuation
- 2014-06-16 KR KR1020157035720A patent/KR20160007662A/ko not_active Application Discontinuation
- 2014-06-16 ES ES14732136T patent/ES2741003T3/es active Active
- 2014-06-16 WO PCT/EP2014/062490 patent/WO2014202492A1/en active Application Filing
- 2014-06-16 TR TR2019/10701T patent/TR201910701T4/tr unknown
- 2014-06-16 EP EP14732136.8A patent/EP3010513B1/en not_active Not-in-force
- 2014-06-16 CN CN201480033396.8A patent/CN105307660A/zh active Pending
- 2014-06-16 BR BR112015029658A patent/BR112015029658A2/pt not_active IP Right Cessation
-
2016
- 2016-03-01 HK HK16102348.7A patent/HK1214502A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP6239745B2 (ja) | 2017-11-29 |
JP2016522228A (ja) | 2016-07-28 |
ES2741003T3 (es) | 2020-02-07 |
CN105307660A (zh) | 2016-02-03 |
MX2015016893A (es) | 2016-04-07 |
HK1214502A1 (zh) | 2016-07-29 |
BR112015029658A2 (pt) | 2017-07-25 |
CA2912816A1 (en) | 2014-12-24 |
RU2015152577A (ru) | 2017-07-24 |
US20160129033A1 (en) | 2016-05-12 |
EP3010513B1 (en) | 2019-06-05 |
WO2014202492A1 (en) | 2014-12-24 |
EP3010513A1 (en) | 2016-04-27 |
PL3010513T3 (pl) | 2019-11-29 |
KR20160007662A (ko) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120318T1 (el) | Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων | |
CY1120506T1 (el) | Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων | |
EA201890125A1 (ru) | Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
BR112016000561B8 (pt) | Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma | |
EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
MX2015014596A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. | |
EA201491447A1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
MX340090B (es) | Analogos de spliceostatina. | |
MX2016004492A (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih). | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
NI201300112A (es) | Composición que comprende aflibercept, ácido folínico, 5 - fluorouracilo (5 - fu) e irinotecano ( folfiri). | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
EA201591024A1 (ru) | Димерные соединения | |
AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
MX2018006953A (es) | Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer. | |
EA201890821A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1 | |
MX366140B (es) | Derivados de urea de piperidinas. | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
EA201591450A1 (ru) | Фармацевтический состав, содержащий гликозаминогликан | |
BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento |